Comparative Pharmacology
Head-to-head clinical analysis: ENSTILAR versus FOAMICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSTILAR versus FOAMICON.
ENSTILAR vs FOAMICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSTILAR is a combination of calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid). Calcipotriene binds to vitamin D receptors, modulating cell proliferation and differentiation. Betamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
FOAMICON is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Apply to affected area once daily for up to 4 weeks. Maximum 100 g/day or 30 g/week. Not for use on face, axillae, or groin.
Adults: 200 mg orally once daily, with or without food.
None Documented
None Documented
Calcipotriol: terminal half-life ~12 hours. Betamethasone dipropionate: terminal half-life ~16-22 hours. Clinically, this supports once-daily application.
Terminal elimination half-life 12-15 hours; clinically, steady-state achieved in ~3 days.
Calcipotriol is primarily excreted via bile/feces (approximately 70% of absorbed dose). Betamethasone dipropionate is mainly excreted renally (60-70% as metabolites) and up to 20-30% via feces. For the combination, renal excretion of betamethasone metabolites predominates, with fecal excretion of calcipotriol.
Primarily renal (65% unchanged, 15% as inactive metabolites); biliary/fecal 20%.
Category C
Category C
Topical Corticosteroid and Vitamin D Analog
Topical Corticosteroid